MedTrace Logo

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

NCT04895202 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2023-08-29

No results posted yet for this study

Summary

This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod as per Swiss label.

Conditions

  • Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Interventions

OTHER

Siponimod

Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceiticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2022-12-20
Completion
2022-12-20

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04895202 on ClinicalTrials.gov